A biopharmaceutical research company with ties in Andover has laid off a third of its workforce as one of the industry leaders in gene therapy goes through a “strategic restructuring.” Sarepta ...

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

On Dr. Prasad’s new watch, the FDA has torpedoed several promising treatments for rare and deadly diseases. This includes an immunotherapy shot that helped a third of advanced melanoma patients who ...

Other changes under Prasad, who was also the agency's chief medical and science officer, included a new policy limiting the ...

This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.

Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.

Key Takeaways Dr. Vinay Prasad is stepping down as top vaccine official at the U.S. Food and Drug AdministrationHis short ...

Indian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...

PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...

From the meme stock revival to Trump's Fed feud, Peter Hodson looks at some of the summer's more bizarre trends ...

Donald Trump reportedly ignored calls from Health Secretary Robert F. Kennedy Jr. not to fire the top vaccine official at the ...